▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2888 by analyst upside · 2026-11-12
OSCR
Oscar Health, Inc.
Healthcare · Market Cap $10B · P/E 14.9x
ANALYST PRICE TARGET
+15.2%
implied upside to consensus target
Current Price $32.11
Consensus Target $37.0
Bull Target $49.0
Bear Target $27.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
0
Hold
6
Sell
1
52-Week Low $10.69
52-Week High $38.5
YTD Return +114.5%
FUNDAMENTALS
Market Cap $10B
P/E Ratio (TTM) 14.9x
Forward P/E 13.6x
EPS (TTM) $2.16
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $17.5B
Profit Margin 4.9%
52-WEEK RANGE
52-Week Low $10.69
52-Week High $38.5
Current Price $32.11
Bear Target $27.0
Bull Target $49.0
● Now $32.11 ● Target $37.0
TRADING DATA
Avg Volume 5.3M
YTD Return +114.5%
Analyst Count 10
Consensus Buy
Upside to Target +15.2%
Last Updated 2026-11-12

ANALYST SUMMARY

Oscar Health, Inc. (OSCR) is currently trading at $32.11 with a Wall Street consensus price target of $37.0, implying potential upside of 15.2% over the next 12 months. 10 analysts currently cover OSCR, with a consensus rating of Buy - 30% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $49.0, while the most cautious has a target of $27.0.

OSCR operates in the Healthcare sector with a market capitalisation of $10B. The stock is up 114.5% year-to-date and is currently trading near the upper end of its 52-week range of $10.69 – $38.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GMED +23.9%
Globus Medical, Inc.
$10B · P/E 18.5x · Buy
BIO -7.6%
Bio-Rad Laboratories, Inc.
$10B · P/E 10.3x · Hold
HSIC +9.3%
Henry Schein, Inc.
$10B · P/E 24.3x · Buy
PODD +19.0%
Insulet Corporation
$10B · P/E 24.2x · Buy
DVA +21.1%
DaVita Inc.
$12B · P/E 13.6x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for OSCR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler - Reiterated
Overweight → Overweight 2026-11-06 14% win rate (7 calls)
UBS - Reiterated
Neutral → Neutral 2026-10-12 33% win rate (6 calls)
Raymond James - Reiterated
Outperform → Outperform 2026-09-18 Building track record
B of A Securities - Reiterated
Underperform → Underperform 2026-09-17 Building track record
Stephens & Co. reit
Equal-Weight → Equal-Weight 2026-09-17 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-09-17 Building track record
Baird - Reiterated
Neutral → Neutral 2026-09-17 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-08-13 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
36
out of 100
Coverage depth
18/30
Consensus clarity
16/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →